Home > Healthcare > Retinal Biologics Market

Retinal Biologics Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032

  • Report ID: GMI4429

Retinal Biologics Market Size

Retinal Biologics Market size will register significant growth between 2024 and 2032, propelled by increasing approvals from prominent regulatory bodies and leading companies. These approvals signify a growing recognition of the efficacy and safety of retinal biologics in treating various ocular diseases. 
 

For instance, in November 2023, Biocon, a leading biotechnology company, announced that its subsidiary, Biocon Biologics Ltd, obtained marketing authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for YESAFILI. This biosimilar of aflibercept had previously received marketing authorization approval from the European Commission (EC) for the European Union (EU) in September 2023. YESAFILI is tailored to treat a range of ophthalmic conditions, including neovascular age-related macular degeneration (wet AMD), diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (branch RVO or central RVO) and myopic choroidal neovascularisation (myopic CNV).
 

As regulators endorse these treatments, pharmaceutical firms are investing heavily in research and development, driving innovation and accessibility. This convergence of regulatory backing and corporate investment promises a bright future for retinal biologics, ensuring improved therapeutic options for patients worldwide.
 

The retinal biologics market is witnessing heightened demand due to the increasing government authorization of marketing for key company products. As regulatory bodies endorse these treatments, confidence in their safety and efficacy grows among healthcare professionals and patients alike. This surge in approvals signifies a pivotal moment in the industry, paving the way for innovative therapies to address retinal diseases. With government backing, leading companies are poised to meet the rising demand, ensuring broader access to advanced retinal biologics worldwide. 
 

For instance, in August 2022, Polpharma Biologics Group BV, Formycon AG, and their Swiss joint venture, Bioeq AG, announced that the European Commission granted marketing authorization for Ranivisio. This treatment, a biosimilar to Lucentis, offered hope for several severe retinal diseases. Ranivisio is specifically indicated for neovascular (wet) age-related macular degeneration (nAMD), proliferative diabetic retinopathy (PDR), visual impairment due to diabetic macular edema (DME) or choroidal neovascularization (CNV), and visual impairment due to macular edema secondary to retinal vein occlusion.
 

Despite its promising trajectory, the retinal biologics market faces significant restraints. High costs associated with research, development, and manufacturing hinder widespread accessibility. Regulatory hurdles, including stringent approval processes, prolong time-to-market for new treatments. 
 

Additionally, limited awareness among healthcare professionals and patients about these biologics poses a challenge to adoption. Moreover, concerns about potential adverse effects and long-term safety profiles contribute to cautious adoption by both practitioners and patients. Addressing these restraints requires collaborative efforts from industry stakeholders to enhance affordability, streamline regulatory pathways, and educate stakeholders about the benefits of retinal biologics.
 

Retinal Biologics Market Trends

The industry is experiencing dynamic trends fueled by increasing partnerships and innovations from industry leaders. Collaborative ventures between companies are facilitating the development of groundbreaking therapies, thus expanding treatment options for retinal diseases. These partnerships enable shared expertise, resources, and access to complementary technologies, accelerating the pace of innovation. Furthermore, leading companies are investing heavily in research and development, driving the discovery of novel biologics and advanced delivery mechanisms. Such trends underscore a promising future for retinal biologics, enhancing patient outcomes and reshaping the landscape of ocular healthcare.
 

To cite an instance, in September 2023, GenSight Biologics, a biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, revealed that its manufacturing partner in the US achieved successful production of the drug substance (DS) for LUMEVOQ. This gene therapy targets Leber Hereditary Optic Neuropathy (LHON) and adheres to Good Manufacturing Practice (GMP) standards.
 

Retinal Biologics Market Analysis

Based on indication, the global retinal biologics industry is segmented into macular degeneration, uveitis, diabetic retinopathy, and others. The industry value from the diabetic retinopathy (DR) segment will record appreciable growth by 2032. The rapid expansion of the diabetic population is one of the key factors driving the prevalence of DR across the globe. The International Diabetes Federation (IDF) estimates that the number of adults living with diabetes will reach 783 million by 2045. Consequently, it may increase the risk of DR, which is one of the most common causes of vision loss among diabetic individuals. These factors are predicted to expedite the retinal biologics industry progress.
 

In terms of distribution channel, the retinal biologics market is bifurcated into hospitals, pharmacies, specialty clinics, and others. The market revenue from the hospital segment will register a notable CAGR through 2032. Hospitals have a wide range of advanced therapeutics available at their disposal, which can play a key role in enhancing a patient’s surgical outcome. Many leading hospital chains have introduced retinal biologic solutions to effectively treat a variety of eye diseases. For example, Max Hospital launched its Max Institute Eye Care (MIEC), an advanced eye care center in South Delhi, India, to offer futuristic technologies and treatments for different eye diseases. Such developments are encouraging more patients to visit hospitals for regular eye checkups, thus bolstering the market outlook.
 

Europe retinal biologics market will display robust gains during the analysis period as the cases of diabetes are increasing in countries such as the UK. This growing incidence rate of diabetes is triggering a rise in the prevalence of retinal disorders, further improving the adoption of retinal biologics. The robust regulatory framework in the European market fosters confidence in the safety and efficacy of these treatments, further fueling demand. With an emphasis on innovative therapies and improved patient outcomes.
 

Retinal Biologics Market Share

Major companies operating in the retinal biologics industry competitive landscape include:

  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Novartis AG, Regeneron
  • OncoGene Pharmaceuticals
     

Retinal Biologics Industry News

In August 2023, Regeneron Pharmaceuticals disclosed that the FDA approved Veopoz (pozelimab-bbfg), a monoclonal antibody, to treat CHAPLE disease in adult and pediatric patients aged one year and older with CD55-deficient protein-losing enteropathy. Additionally, the FDA greenlit Eylea HD Injection 8 mg, an elevated dosage of Eylea, for the treatment of diabetic retinopathy, wet age-related macular degeneration (wAMD), and diabetic macular edema (DME).

What Information does this report contain?

Historical data coverage: 2018 to 2023; Growth Projections: 2024 to 2032.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Pre Book Now


 Download PDF